阿貝庫瑪市場規模、佔有率和成長分析：按產品類型、適應症、治療線、最終用戶、分銷管道和地區分類－2026-2033年產業預測

2024 年全球 Abecma 市值為 11.2 億美元，預計到 2025 年將成長至 13.3 億美元，到 2033 年將成長至 51 億美元，在預測期（2026-2033 年）內複合年成長率為 18.4%。

全球avecma市場正經歷顯著成長，這主要得益於復發/難治性多發性骨髓瘤患病率的上升以及既往接受過多種藥物治療的患者對新療法的強烈臨床需求。 CAR-T細胞療法的進步、治療機構產能的提升以及對創新腫瘤解決方案的關注，都在推動市場需求的成長。生產規模和物流的改進縮短了靜脈輸注時間，使更多患者能夠得到高效治療。此外，循證醫學證據的累積、醫保政策的完善以及基於療效的補償機制的強化，預計將有助於avecma的長期廣泛應用。然而，高昂的治療成本、複雜的生產流程、有限的產能、嚴格的監管、安全隱患以及來自其他BCMA標靶治療的競爭等挑戰，可能會阻礙avecma的市場滲透。

全球Abecma市場按產品類型、適應症、治療線、最終用戶、分銷管道和地區進行細分。依產品類型分類，市場分為靜脈注射懸浮液和其他類型。依適應症分類，市場分為復發性多發性骨髓瘤、難治性多發性骨髓瘤及其他類型。依治療線分類，市場分為四線治療、五線以上治療及其他類型。依最終用戶分類，市場分為專科腫瘤中心、綜合醫院、研究機構和其他機構。依分銷管道分類，市場分為醫院藥房、專科藥房和其他管道。依地區分類，市場分為北美、歐洲、亞太、拉丁美洲以及中東和非洲。

全球Abecma市場的成長要素

全球Abecma市場主要受惠於CAR-T細胞工程技術的進步。這些進步顯著提高了治療的特異性和持久性，從而使不同患者群體獲得更一致的臨床療效。生產流程的創新、最佳化的載體設計以及改進的細胞分選技術相結合，提高了產品的可靠性，並最大限度地減少了患者反應的差異。這項技術進步生態系統不僅增強了臨床醫師的信心，也促進了Abecma進一步整合到治療方案中。此外，它還透過鼓勵機構投資必要的基礎設施，並促進旨在改善管理、監測和管理實踐的合作，改善了Abecma市場的長期前景。

全球Abecma市場面臨的限制因素

由於Abecma療法在給藥方面存在複雜的物流挑戰，其全球市場面臨許多限制因素。對專業治療中心、訓練有素的專業人員以及嚴格的細胞材料管理流程的依賴，阻礙了該治療方法的廣泛應用。缺乏專門物流支援的醫療機構，例如缺乏用於給藥時間安排、病患監測和跨部門協調的機構，可能難以接收患者，並限制其有效實施治療的能力。這些物流挑戰阻礙了Abecma的廣泛應用，造成許多障礙，使得許多醫療機構無法將這種創新治療方法納入其治療方案，從而限制了其在醫療保健市場的整體覆蓋範圍。

全球Abecma市場趨勢

全球Abecma市場正呈現出醫療服務分散化的顯著趨勢，其特徵是門診和社區管理網路的擴張。隨著學術機構與地方醫院之間合作的加強，醫療服務體係得到強化，這一轉變為市場相關人員創造了新的商機。標準化訓練、遠距遠端醫療監測和高效轉診途徑等方面的創新正在加速病患轉診，提升地方醫療機構的服務能力，並透過統一的診療規範確保醫療安全。這種不斷變化的格局凸顯了改善醫療服務可近性和提高病患管理效率的努力，為Abecma市場在更整合的醫療環境中實現永續成長奠定了基礎。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球阿貝庫瑪市場規模：依產品類型分類

• 靜脈懸浮液懸浮液
• 其他

全球阿貝庫瑪市場規模：依適應症分類

• 復發性多發性骨髓瘤
• 難治性多發性骨髓瘤
• 其他

全球黃斑部病變腫瘤市場規模：依治療線分類

• 四線療法
• 從第五行開始
• 其他

全球阿貝庫瑪市場規模：依最終用戶分類

• 專科癌症中心
• 綜合醫院
• 研究機構
• 其他

全球阿貝庫瑪市場規模：按分銷管道分類

• 醫院藥房
• 專科藥房
• 其他

全球 Abekuma 市場規模：按地區

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Bristol Myers Squibb
• 2seventy bio
• Johnson & Johnson（Janssen）
• Novartis
• Gilead Sciences（Kite Pharma）
• Amgen
• Pfizer
• Sanofi
• GlaxoSmithKline（GSK）
• Roche
• Regeneron Pharmaceuticals
• Takeda Pharmaceutical
• AbbVie
• Legend Biotech
• Poseida Therapeutics
• Cellectis
• Precision BioSciences
• Allogene Therapeutics
• Cartesian Therapeutics
• Arcellx

結論與建議

Global Abecma Market size was valued at USD 1.12 Billion in 2024 and is poised to grow from USD 1.33 Billion in 2025 to USD 5.10 Billion by 2033, growing at a CAGR of 18.4% during the forecast period (2026-2033).

The global Abecma market is experiencing significant growth driven by the rising prevalence of relapsed and refractory multiple myeloma and a strong clinical need among heavily pretreated patients. Advancements in CAR-T cell therapy, coupled with expanded treatment center capabilities and a focus on innovative oncology solutions, are boosting demand. Improvements in manufacturing scalability and logistics are decreasing vein-to-vein time, allowing more patients to be treated efficiently. Additionally, enhancements in evidence generation, reimbursement policies, and outcome-based compensation are expected to support Abecma's long-term uptake. However, challenges such as high treatment costs, complex manufacturing processes, limited production capacity, stringent regulations, safety concerns, and competition from other BCMA-targeted therapies may hinder market penetration.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Abecma market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Abecma Market Segments Analysis

Global Abecma market is segmented by product type, indication, treatment line, end-user, distribution channel, and region. Based on product type, the market is segmented into suspension for intravenous infusion and others. Based on indication, the market is segmented into relapsed multiple myeloma, refractory multiple myeloma, and others. Based on treatment line, the market is segmented into fourth-line therapy, fifth-line and beyond, and others. Based on end-user, the market is segmented into specialized oncology centers, multi-specialty hospitals, research institutes, and others. Based on distribution channel, the market is segmented into hospital pharmacies, specialty pharmacies, and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Driver of the Global Abecma Market

The global Abecma market is significantly driven by advancements in CAR T cell engineering, which have markedly enhanced therapeutic specificity and persistence, leading to more consistent clinical outcomes across varied patient demographics. Innovations in manufacturing processes, optimized vector design, and refined cell selection techniques have collectively bolstered product reliability, minimizing variability in patient responses. This ecosystem of technical progress not only strengthens clinician confidence but also promotes greater integration of Abecma into treatment protocols. Additionally, it encourages institutional investments in necessary infrastructure and fosters collaborative efforts aimed at improving delivery, monitoring, and management practices, thus enhancing the long-term outlook of the Abecma market.

Restraints in the Global Abecma Market

The global Abecma market faces significant restraints due to the intricate logistics associated with its administration. The reliance on specialized treatment centers, highly trained professionals, and strict protocols for managing cellular materials complicates the distribution of the therapy. Institutions lacking dedicated logistical support for timing, patient monitoring, and inter-departmental coordination may struggle to accommodate patients, limiting their ability to effectively implement the treatment. These logistical challenges hinder the widespread adoption of Abecma, creating barriers that prevent many facilities from integrating this innovative therapy into their treatment offerings and reducing its overall reach in the healthcare market.

Market Trends of the Global Abecma Market

The Global Abecma market is witnessing a notable trend towards decentralized care delivery, characterized by the expansion of outpatient and regional administration networks. This shift creates new business opportunities for market players as collaborations between academic centers and community hospitals enhance care provision. Innovations in standardized training, telemedicine-enabled monitoring, and efficient referral pathways are facilitating quicker patient transitions, increasing capacity development in regional facilities, and ensuring safe care through harmonized protocols. This evolving landscape underscores a commitment to improving accessibility and streamlining patient management, positioning the Abecma market for sustained growth in a more integrated healthcare environment.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Abecma Market Size by Product Type & CAGR (2026-2033)

• Market Overview
• Suspension for Intravenous Infusion
• Others

Global Abecma Market Size by Indication & CAGR (2026-2033)

• Market Overview
• Relapsed Multiple Myeloma
• Refractory Multiple Myeloma
• Others

Global Abecma Market Size by Treatment Line & CAGR (2026-2033)

• Market Overview
• Fourth-line Therapy
• Fifth-line and Beyond
• Others

Global Abecma Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Specialized Oncology Centers
• Multi-specialty Hospitals
• Research Institutes
• Others

Global Abecma Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Specialty Pharmacies
• Others

Global Abecma Market Size & CAGR (2026-2033)

• North America (Product Type, Indication, Treatment Line, End-User, Distribution Channel)
  • US
  • Canada
• Europe (Product Type, Indication, Treatment Line, End-User, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product Type, Indication, Treatment Line, End-User, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product Type, Indication, Treatment Line, End-User, Distribution Channel)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product Type, Indication, Treatment Line, End-User, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Bristol Myers Squibb
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• 2seventy bio
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (Janssen)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences (Kite Pharma)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline (GSK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Legend Biotech
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Poseida Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cellectis
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Precision BioSciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Allogene Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cartesian Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Arcellx
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations